EZR and breast carcinoma: Next, we depleted ezrin using siRNA in MDA-MB-231 and ZR-75-1 breast cancer cells, which have high ezrin levels and exhibit greater resistance to DOX and DTX compared with MCF-7 or T-47D cells and assessed the effect on chemotherapeutic drug sensitivity (see Fig. 2A for ezrin representative immunoblots and quantitation of knockdown levels).